Abstract:Gaining a better understanding of autoprotection against drug-induced liver injury (DILI) may provide new strategies for its prevention and therapy. However, little is known about the underlying mechanisms of this phenomenon. We used single-cell RNA sequencing to characterize the dynamics and functions of hepatic non-parenchymal cells (NPCs) in autoprotection against DILI, using acetaminophen (APAP) as a model drug. Autoprotection was modeled through pretreatment with a mildly hepatotoxic dose of APAP in mice, followed by a higher dose in a secondary challenge. NPC subsets and dynamic changes were identified in the APAP (hepatotoxicity-sensitive) and APAP-resistant (hepatotoxicity-resistant) groups. A chemokine (C-C motif) ligand 2 thorn endothelial cell subset almost disappeared in the APAP-resistant group, and an R-spondin 3 thorn endothelial cell subset promoted hepatocyte proliferation and played an important role in APAP autoprotection. Moreover, the dendritic cell subset DC-3 may protect the liver from APAP hepatotoxicity by inducing low reactivity and suppressing the autoimmune response and occurrence of inflammation. DC-3 cells also promoted angiogenesis through crosstalk with endothelial cells via vascular endothelial growth factor-associated ligand-receptor pairs and facilitated liver tissue repair in the APAP-resistant group. In addition, the natural killer cell subsets NK-3 and NK-4 and the Sca-1 -CD62L thorn natural killer T cell subset may promote autoprotection through interferon-g-dependent pathways. Furthermore, macrophage and neutrophil subpopulations with anti-inflammatory phenotypes promoted tolerance to APAP hepatotoxicity. Overall, this study reveals the dynamics of NPCs in the resistance to APAP hepatotoxicity and provides novel insights into the mechanism of autoprotection against DILI at a high resolution. & COPY; 2023 The Author(s). Published by Elsevier B.V. on behalf of Xi'an Jiaotong University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Innate immune regulation in inflammation resolution and liver regeneration in drug-induced liver injury

Single-cell RNA Sequencing Reveals the Dynamics of Hepatic Non-Parenchymal Cells in Autoprotection Against Acetaminophen-Induced Hepatotoxicity

T‐helper Cell‐mediated Factors in Drug‐induced Liver Injury

Dissecting the molecular pathophysiology of drug-induced liver injury

The immunological mechanisms and therapeutic potential in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity

Progress in research on the pathogenesis of immune regulation and idiosyncratic drug-induced liver injury

Hepatic Macrophages in Drug-Induced Liver Injury

The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury

Insights gained into the injury mechanism of drug and herb induced liver injury in the hepatic microenvironment

Targeting Innate Immune Responses to Attenuate Acetaminophen-Induced Hepatotoxicity

CCL5 deficiency promotes liver repair by improving inflammation resolution and liver regeneration through M2 macrophage polarization

Advances in drug-induced liver injury research: in vitro models, mechanisms, omics and gene modulation techniques

The Dual Role of Innate Immune Response in Acetaminophen-Induced Liver Injury

The Roles Of Innate Immune Cells In Liver Injury And Regeneration

Progress in the treatment of drug-induced liver injury with natural products

The dual role of immune response in acetaminophen hepatotoxicity: Implication for immune pharmacological targets

Role of Gut Microecology in the Pathogenesis of Drug-Induced Liver Injury and Emerging Therapeutic Strategies

Alteration of Bile Acids and Omega-6 PUFAs Are Correlated With the Progression and Prognosis of Drug-Induced Liver Injury

The Beneficial Roles of SIRT1 in Drug-Induced Liver Injury

Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review

Clinical features of drug-induced liver failure and related diagnosis and treatment strategies